PT3067358T - Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica - Google Patents

Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica

Info

Publication number
PT3067358T
PT3067358T PT152015194T PT15201519T PT3067358T PT 3067358 T PT3067358 T PT 3067358T PT 152015194 T PT152015194 T PT 152015194T PT 15201519 T PT15201519 T PT 15201519T PT 3067358 T PT3067358 T PT 3067358T
Authority
PT
Portugal
Prior art keywords
polycyclic
pharmaceutical use
carbamoylpyridone compounds
carbamoylpyridone
compounds
Prior art date
Application number
PT152015194T
Other languages
English (en)
Portuguese (pt)
Inventor
Jin Haolun
G Taylor James
M Bacon Elizabeth
E Lazerwith Scott
Mish Michael
R Cai Zhenhong
J Cottell Jeromy
Pyun Hyung-Jung
Alejandra Trejo Martin Teresa
Anthony Morganelli Philip
Ji Mingzhe
Chen Xiaowu
C Desai Manoj
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3067358(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PT3067358T publication Critical patent/PT3067358T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT152015194T 2012-12-21 2013-12-19 Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica PT3067358T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261745375P 2012-12-21 2012-12-21
US201361788397P 2013-03-15 2013-03-15
US201361845803P 2013-07-12 2013-07-12

Publications (1)

Publication Number Publication Date
PT3067358T true PT3067358T (pt) 2019-11-18

Family

ID=49917297

Family Applications (3)

Application Number Title Priority Date Filing Date
PT152015194T PT3067358T (pt) 2012-12-21 2013-12-19 Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica
PT138159371T PT2822954E (pt) 2012-12-21 2013-12-19 Compostos carbamoilpiridona policíclicos e seu uso farmacêutico
PT191851211T PT3608325T (pt) 2012-12-21 2013-12-19 Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT138159371T PT2822954E (pt) 2012-12-21 2013-12-19 Compostos carbamoilpiridona policíclicos e seu uso farmacêutico
PT191851211T PT3608325T (pt) 2012-12-21 2013-12-19 Compostos carbamoílpiridona policíclicos e sua utilização farmacêutica

Country Status (41)

Country Link
US (6) US9216996B2 (OSRAM)
EP (4) EP2822954B1 (OSRAM)
JP (7) JP6028105B2 (OSRAM)
KR (8) KR102351912B1 (OSRAM)
CN (4) CN107674086B (OSRAM)
AP (1) AP2015008510A0 (OSRAM)
AR (1) AR094197A1 (OSRAM)
AU (6) AU2013361401C1 (OSRAM)
BR (2) BR112015014714B1 (OSRAM)
CA (3) CA2893843C (OSRAM)
CL (3) CL2015001756A1 (OSRAM)
CR (2) CR20170279A (OSRAM)
CY (3) CY1117570T1 (OSRAM)
DK (3) DK3067358T3 (OSRAM)
EA (2) EA037633B1 (OSRAM)
ES (3) ES2577283T3 (OSRAM)
HR (3) HRP20220899T1 (OSRAM)
HU (4) HUE059688T2 (OSRAM)
IL (4) IL239316A (OSRAM)
LT (3) LT3067358T (OSRAM)
LU (1) LUC00083I2 (OSRAM)
MD (3) MD4736C1 (OSRAM)
ME (1) ME02400B (OSRAM)
MX (5) MX372534B (OSRAM)
MY (2) MY164352A (OSRAM)
NL (1) NL300947I2 (OSRAM)
NO (1) NO2018026I2 (OSRAM)
NZ (2) NZ709260A (OSRAM)
PE (2) PE20151499A1 (OSRAM)
PH (3) PH12016500389A1 (OSRAM)
PL (3) PL3067358T3 (OSRAM)
PT (3) PT3067358T (OSRAM)
RS (1) RS54873B1 (OSRAM)
SG (1) SG11201504857SA (OSRAM)
SI (3) SI3067358T1 (OSRAM)
SM (1) SMT201600157B (OSRAM)
TW (5) TWI693224B (OSRAM)
UA (2) UA114351C2 (OSRAM)
UY (1) UY35213A (OSRAM)
WO (1) WO2014100323A1 (OSRAM)
ZA (2) ZA201507997B (OSRAM)

Families Citing this family (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2729448E (pt) 2011-07-06 2015-12-02 Gilead Sciences Inc Compostos para o tratamento de vih
TWI572605B (zh) 2012-04-26 2017-03-01 必治妥美雅史谷比公司 血小板聚集之抑制劑
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
LT2945939T (lt) 2013-01-15 2020-07-27 Incyte Holdings Corporation Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai
NO2865735T3 (OSRAM) 2013-07-12 2018-07-21
PL3019503T3 (pl) 2013-07-12 2018-01-31 Gilead Sciences Inc Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
EP3036238A1 (en) 2013-08-23 2016-06-29 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
ZA201503540B (en) * 2014-05-20 2016-10-26 Cipla Ltd Process for preparing polycyclic carbamoyl pyridone derivatives
MY185765A (en) 2014-06-17 2021-06-06 Pfizer Substituted dihydroisoquinolinone compounds
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) * 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (OSRAM) * 2014-06-20 2018-06-23
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016027879A1 (ja) 2014-08-22 2016-02-25 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016036759A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
WO2016090545A1 (en) * 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
TWI695003B (zh) * 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
ES2705709T3 (es) 2014-12-24 2019-03-26 Gilead Sciences Inc Compuestos de isoquinolina para el tratamiento del VIH
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2016216673B2 (en) 2015-03-04 2017-02-02 Gilead Sciences, Inc. Toll like receptor modulator compounds
EP3277691B1 (en) * 2015-04-02 2019-01-30 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
AU2016256125B9 (en) * 2015-04-28 2020-02-20 Shionogi And Co., Ltd. Substituted polycyclic pyridone derivative and prodrug thereof
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
US20210292327A1 (en) 2015-08-26 2021-09-23 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
JP2018529714A (ja) 2015-09-30 2018-10-11 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための化合物および組合せ物
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
BR102016026127A2 (pt) 2015-11-09 2017-05-16 Gilead Sciences Inc composições terapêuticas para o tratamento do vírus da imunodeficiência humana
EA201891186A1 (ru) 2015-12-15 2018-12-28 Джилид Сайэнс, Инк. Антитела, нейтрализующие вирус иммунодефицита человека
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP4299133A3 (en) * 2016-06-23 2024-03-13 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
WO2018005328A1 (en) * 2016-06-27 2018-01-04 Concert Pharmaceuticals, Inc. Deuterated bictegravir
JP6716785B2 (ja) 2016-08-19 2020-07-01 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
AU2017318601B2 (en) 2016-09-02 2020-09-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
US10640499B2 (en) 2016-09-02 2020-05-05 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
WO2018064071A1 (en) 2016-09-27 2018-04-05 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
ES2992772T3 (en) 2016-09-28 2024-12-18 Gilead Sciences Inc Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection
EP3532478B1 (en) 2016-10-27 2021-05-26 Gilead Sciences, Inc. Crystalline form of darunavir free base
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CN108250215B (zh) * 2016-12-28 2022-04-19 华创合成制药股份有限公司 一种新型抗hiv药物及其制备方法和用途
TW202510891A (zh) 2017-01-31 2025-03-16 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
CN106860464A (zh) * 2017-02-16 2017-06-20 江苏艾迪药业有限公司 用于联合抗病毒治疗的药物组合物及应用
CN106860414B (zh) * 2017-02-16 2019-12-24 江苏艾迪药业股份有限公司 一种用于抗hiv的复方制剂及其制备方法与应用
ZA201803942B (en) 2017-06-13 2021-05-26 Cipla Ltd Novel processes for preparation of integrase inhibitor
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
JP7287906B2 (ja) 2017-06-30 2023-06-06 ヴィーブ ヘルスケア カンパニー 組み合わせ並びにその使用及びそれによる治療
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
US20200171039A1 (en) * 2017-08-09 2020-06-04 Viiv Healthcare Company Combinations and uses and treatments
US20200246351A1 (en) 2017-08-09 2020-08-06 Viiv Healthcare Company Combinations and uses and treatments thereof
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
MX2020003469A (es) * 2017-10-06 2020-08-03 Shionogi & Co Proceso estereoselectivo para preparar derivados de piridona policiclicos sustituidos.
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
EP3700573A1 (en) 2017-10-24 2020-09-02 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
PL3706762T3 (pl) 2017-12-07 2025-02-10 Emory University N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
KR102497051B1 (ko) * 2018-01-19 2023-02-09 길리애드 사이언시즈, 인코포레이티드 빅테그라비르의 대사물
EP3749673B1 (en) 2018-02-09 2022-03-16 Sandoz AG Crystalline form of bictegravir sodium
ES2958828T3 (es) 2018-02-15 2024-02-15 Gilead Sciences Inc Derivados de piridina y su uso para tratar una infección por VIH
PL3752496T3 (pl) 2018-02-16 2023-11-27 Gilead Sciences, Inc. Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
CN109020911B (zh) * 2018-04-16 2022-06-28 常州制药厂有限公司 用于制备bictegravir的中间体及其制备方法
WO2019207602A1 (en) 2018-04-26 2019-10-31 Mylan Laboratories Limited Polymorphic forms of bictegravir and its sodium salt
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
CN110526930B (zh) * 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
SG11202011386QA (en) 2018-05-31 2020-12-30 Shionogi & Co Polycyclic pyridone derivative
EP4257137A3 (en) 2018-05-31 2023-11-01 Shionogi & Co., Ltd Polycyclic carbamoylpyridone derivatives for the treatment of hiv
EP3815689A4 (en) 2018-06-27 2022-04-20 National University Corporation Hokkaido University ARENAVIRUS GROWTH INHIBITOR COMPRISING A POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE
WO2020003151A1 (en) 2018-06-28 2020-01-02 Honour Lab Limited Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1', 2':4,5]pyrazino[2,1-b] [1,3] oxazepin-8-olate and its polymorphic form
PE20210685A1 (es) 2018-07-03 2021-04-08 Gilead Sciences Inc Anticuerpos que se dirigen al gp120 de vih y metodos de uso
WO2020012408A2 (en) * 2018-07-12 2020-01-16 Laurus Labs Limited A process for purification of protected polycyclic carbamoylpyridone derivatives
CN120078775A (zh) 2018-07-16 2025-06-03 吉利德科学公司 用于治疗hiv的衣壳抑制剂
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
CA3113011A1 (en) 2018-09-19 2020-03-26 Gilead Sciences, Inc. Integrase inhibitors for the prevention of hiv
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
WO2020086555A1 (en) * 2018-10-22 2020-04-30 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
MX2021005047A (es) 2018-10-31 2021-09-08 Gilead Sciences Inc Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1.
EP3653629A1 (en) * 2018-11-16 2020-05-20 Sandoz AG Acid addition salts of an integrase strand transfer inhibitor
US20220175936A1 (en) 2018-11-29 2022-06-09 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
US12195480B2 (en) 2019-02-07 2025-01-14 Cipla Limited Polymorphs of integrase inhibitor
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
AU2020231115B2 (en) 2019-03-07 2025-02-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
DK3934757T3 (da) 2019-03-07 2023-04-17 Inst Of Organic Chemistry And Biochemistry Ascr V V I 2'3'-cykliske dinukleotider og prodrugs deraf
WO2020197991A1 (en) * 2019-03-22 2020-10-01 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US20200347036A1 (en) 2019-04-17 2020-11-05 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TW202231277A (zh) 2019-05-21 2022-08-16 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
CN110229174A (zh) * 2019-05-22 2019-09-13 博诺康源(北京)药业科技有限公司 Bictegravir原料药基因毒性杂质的合成方法
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
CN110263404B (zh) * 2019-06-12 2023-03-21 江苏大学 一种基于dpm模型的一体化预制泵站沉积特性的计算方法
US12486286B2 (en) * 2019-06-18 2025-12-02 Laurus Labs Limited Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
PE20220231A1 (es) 2019-06-25 2022-02-07 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
EP3999107A1 (en) 2019-07-16 2022-05-25 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN110698473B (zh) * 2019-10-08 2020-12-18 浙江大学 哌嗪酮并羟基吡啶酮-5-羧基类化合物及制备和应用
AU2020391466B2 (en) 2019-11-26 2024-05-23 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
JP7776335B2 (ja) * 2019-11-28 2025-11-26 塩野義製薬株式会社 多環性ピリドピラジン誘導体
EP4066839A4 (en) 2019-11-28 2023-12-27 Shionogi & Co., Ltd PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
IL295677A (en) 2020-02-24 2022-10-01 Gilead Sciences Inc Tetracyclic compounds for treating hiv infection
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
CN113698420A (zh) * 2020-05-22 2021-11-26 上海迪赛诺生物医药有限公司 比克替拉韦钠的新晶型及其制备方法
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
US12110305B2 (en) 2020-08-07 2024-10-08 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
US12421235B2 (en) * 2020-09-30 2025-09-23 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN114426540B (zh) * 2020-10-29 2024-04-26 上海拓界生物医药科技有限公司 吡啶并[1,2-a]吡嗪-1,8-二酮类前药衍生物、其制备方法及其应用
TW202227445A (zh) * 2020-10-30 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 抑制基因缺陷的ｈｉｖ病毒的用途
PT4244396T (pt) 2020-11-11 2025-10-20 Gilead Sciences Inc Métodos de identificação de doentes com hiv sensíveis à terapia com anticorpos dirigidos ao sítio de ligação cd4 da gp120
PT4196479T (pt) 2021-01-19 2024-01-03 Gilead Sciences Inc Compostos de piridotriazinas substituídos e suas utilizações
EP4281076A4 (en) * 2021-01-22 2024-07-31 Laurus Labs Limited Processes for purification of bictegravir intermediates
CN114835730A (zh) * 2021-02-02 2022-08-02 齐鲁制药有限公司 一种制备多环氨基甲酰基吡啶酮化合物的方法
WO2022224120A1 (en) 2021-04-19 2022-10-27 Honour Lab Limited Polymorphic forms of bictegravir potassium
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
JP7686086B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117751118A (zh) * 2021-07-30 2024-03-22 吉斯凯(苏州)制药有限公司 大环吡啶酮类化合物及其应用
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
WO2023102523A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CN114605437A (zh) * 2022-04-01 2022-06-10 遵义医科大学 连续一锅法制备三个替拉韦药物的合成工艺
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2023248240A1 (en) 2022-06-21 2023-12-28 Mylan Laboratories Limited Polymorphic forms of bictegravir sodium
TW202434566A (zh) 2022-07-01 2024-09-01 美商基利科學股份有限公司 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物
CN119677546A (zh) 2022-07-12 2025-03-21 吉利德科学公司 Hiv免疫原性多肽和疫苗及其用途
CA3265134A1 (en) 2022-08-26 2024-02-29 Gilead Sciences Inc DOSING AND PLANNING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES
WO2024061257A1 (zh) * 2022-09-20 2024-03-28 吉斯凯(苏州)制药有限公司 多环氮杂环酮类化合物及其应用
EP4598934A1 (en) 2022-10-04 2025-08-13 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
AU2024259111A1 (en) 2023-04-19 2025-10-16 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於ｈｉｖ之治療性化合物
US20250051375A1 (en) 2023-05-31 2025-02-13 Gilead Sciences, Inc. Anti-hiv compounds
WO2025029247A1 (en) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
EP4529922A1 (en) 2023-09-29 2025-04-02 Gilead Sciences, Inc. Pharmaceutical formulations of bictegravir and lenacapavir
US20250073172A1 (en) 2023-08-15 2025-03-06 Gilead Sciences, Inc. Pharmaceutical formulations of bictegravir and lenacapavir
WO2025042394A1 (en) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025076542A1 (en) 2023-10-05 2025-04-10 Jones R Brad Atovaquone as an ros inducer for use in the elimination of hiv-infected t-cells
US20250120989A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025137245A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
WO2025212814A1 (en) 2024-04-03 2025-10-09 Gilead Sciences, Inc. Anti-hiv compounds

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE788516A (fr) 1971-09-10 1973-03-07 Lonza Ag Procede de fabrication d'esters alcoxyacetylacetiques
GB1528382A (en) 1974-12-26 1978-10-11 Teijin Ltd Cyclopentene diols and acyl esters thereof and processes for their preparation
DE2658401A1 (de) 1976-12-23 1978-07-06 Merck Patent Gmbh Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4575694A (en) 1984-03-05 1986-03-11 Allied Corporation Coaxial connector
DE3900735A1 (de) 1989-01-12 1990-07-26 Hoechst Ag Neue mehrfunktionelle (alpha)-diazo-(beta)-ketoester, verfahren zu ihrer herstellung und deren verwendung
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
DE4014649A1 (de) 1990-05-08 1991-11-14 Hoechst Ag Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
SE9702772D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
AU1403099A (en) 1997-11-14 1999-06-07 Merck & Co., Inc. Alpha-1a adrenergic receptor antagonists
BR9915194A (pt) 1998-11-09 2001-08-07 Black James Foundation Composto, método para fabricar o mesmo, composição farmacêutica, e, método para fabricar a mesma
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
US6620841B1 (en) 1998-12-25 2003-09-16 Shionogi & Co., Ltd. Aromatic heterocycle compounds having HIV integrase inhibiting activities
AU2001262732A1 (en) 2000-06-14 2001-12-24 Shionogi And Co., Ltd. Inhibitor for enzyme having two divalent metal ions as active centers
ATE364385T1 (de) * 2000-10-12 2007-07-15 Merck & Co Inc Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
EP2181985B1 (en) 2001-08-10 2011-10-26 Shionogi & Co., Ltd. Antiviral Agent
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
NZ532018A (en) 2001-10-03 2004-12-24 Ucb S Pyrrolidinone derivatives
CA2463976C (en) 2001-10-26 2007-02-13 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
WO2004004657A2 (en) 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
JP2006506352A (ja) 2002-09-11 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害剤として有用なジヒドロキシピリドピラジン−１，６−ジオン化合物
AR042095A1 (es) 2002-11-20 2005-06-08 Japan Tobacco Inc Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih
US20040224917A1 (en) 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
CN101014571A (zh) 2004-01-30 2007-08-08 默克公司 用作hiv整合酶抑制剂的n－苄基－3,4－二羟基吡啶－2－羧酰胺类和n－苄基－2,3－二羟基吡啶－4－羧酰胺类化合物
JP4859676B2 (ja) 2004-02-11 2012-01-25 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害剤
CN101014574A (zh) 2004-03-09 2007-08-08 默克公司 Hiv整合酶抑制剂
WO2005110399A2 (en) 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
EP1755586A2 (en) 2004-04-29 2007-02-28 The Regents of the University of California Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors
CN1964975B (zh) 2004-05-07 2011-11-30 默沙东公司 Hiv整合酶抑制剂
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
CN1953751A (zh) * 2004-05-17 2007-04-25 泰博特克药品有限公司 取代的1－苯基－1,5－二氢－吡啶并－[3,2－b]吲哚－2－酮和其它的hiv抑制剂的组合物
WO2005113509A1 (en) 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005112930A1 (en) 2004-05-21 2005-12-01 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
US7550463B2 (en) 2004-09-15 2009-06-23 Shionogi & Co., Ltd. Carbamoylpyridone derivatives having inhibitory activity against HIV integrase
JP2006118669A (ja) 2004-10-25 2006-05-11 Sanoh Industrial Co Ltd 樹脂チューブ
WO2006066414A1 (en) 2004-12-23 2006-06-29 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
EP1852434B1 (en) 2005-02-21 2011-07-13 Shionogi Co., Ltd. Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
JP4295353B2 (ja) 2005-04-28 2009-07-15 スミスクライン ビーチャム コーポレーション Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
WO2006125048A2 (en) 2005-05-16 2006-11-23 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2616314A1 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of hiv
JP5131689B2 (ja) 2005-10-27 2013-01-30 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
SG170796A1 (en) 2005-12-30 2011-05-30 Gilead Sciences Inc Us Methods for improving the pharmacokinetics of hiv integrase inhibitors
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
EP2452682A1 (en) 2006-02-01 2012-05-16 Japan Tobacco, Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
AU2007223260C1 (en) 2006-03-06 2011-02-03 Japan Tobacco Inc. Method for producing 4-oxoquinoline compound
US8420821B2 (en) 2006-03-06 2013-04-16 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
JP2009543865A (ja) 2006-07-19 2009-12-10 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド ピリジノンジケト酸：併用療法におけるｈｉｖ複製の阻害剤
MX2009002689A (es) 2006-09-12 2009-03-26 Gilead Sciences Inc Proceso e intermediarios para preparar inhibidores de integrasa.
US20100216834A1 (en) 2006-10-18 2010-08-26 Isaacs Richard C A Hiv integrase inhibitors
ES2602784T3 (es) 2007-02-23 2017-02-22 Gilead Sciences, Inc. Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos
US20080280945A1 (en) 2007-05-09 2008-11-13 Sachin Lohani Crystalline forms of an HIV integrase inhibitor
EP2167088A1 (en) 2007-06-29 2010-03-31 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
KR20100028656A (ko) 2007-06-29 2010-03-12 길리애드 사이언시즈, 인코포레이티드 치료 조성물 및 그의 용도
US20090012103A1 (en) 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
CA2693340A1 (en) 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Pyrone analog compositions and methods
AR068403A1 (es) 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
WO2009062285A1 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
GB0803019D0 (en) 2008-02-19 2008-03-26 Btg Int Ltd Fluorinated compounds
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
US20100272811A1 (en) 2008-07-23 2010-10-28 Alkermes,Inc. Complex of trospium and pharmaceutical compositions thereof
EP2320909B8 (en) 2008-07-25 2016-03-30 VIIV Healthcare Company Chemical compounds
WO2010011816A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011819A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011812A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010011815A1 (en) 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
WO2010068262A1 (en) 2008-12-11 2010-06-17 Glaxosmithkline Llc Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
EP3210603A1 (en) * 2008-12-11 2017-08-30 Shionogi & Co., Ltd Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
AU2009333653B2 (en) 2008-12-17 2015-09-10 Merck Patent Gmbh C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
EA021313B1 (ru) 2009-02-06 2015-05-29 Джилид Сайэнс, Инк. Таблетки для комбинированной терапии
WO2010110231A1 (ja) 2009-03-26 2010-09-30 塩野義製薬株式会社 置換された３－ヒドロキシ－４－ピリドン誘導体
TWI518084B (zh) * 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
PL2444400T3 (pl) 2009-06-15 2018-08-31 Shionogi & Co., Ltd. Podstawiona policykliczna pochodna karbamoilopirydonowa
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
WO2011028044A2 (ko) 2009-09-02 2011-03-10 이화여자대학교 산학협력단 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
NZ627827A (en) 2010-01-27 2016-02-26 Viiv Healthcare Co Antiviral combinations involving (3s, 11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
SG183484A1 (en) 2010-02-26 2012-09-27 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
WO2012003498A1 (en) 2010-07-02 2012-01-05 Gilead Sciences, Inc. 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
EP3127908B1 (en) 2010-08-05 2018-11-28 Shionogi & Co., Ltd Process for preparing compound having hiv integrase inhibitory activity
HRP20181250T1 (hr) 2010-09-24 2018-10-05 Shionogi & Co., Ltd. Predlijek iz supstituiranog policikličkog derivata karbamoilpiridona
ES2524408T5 (es) 2010-11-19 2022-04-25 Gilead Sciences Inc Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato
WO2012106534A2 (en) 2011-02-02 2012-08-09 The Regents Of The University Of California Hiv integrase inhibitors
WO2012145728A1 (en) 2011-04-21 2012-10-26 Gilead Sciences, Inc. Benzothiazole compounds and their pharmaceutical use
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
WO2012151567A1 (en) 2011-05-05 2012-11-08 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for preventing and treating influenza
US9121496B2 (en) 2011-06-29 2015-09-01 Arvinmeritor Technology, Llc Drive axle system and a method of control
PT2729448E (pt) 2011-07-06 2015-12-02 Gilead Sciences Inc Compostos para o tratamento de vih
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
PL2729130T3 (pl) 2011-07-07 2018-02-28 Janssen Sciences Ireland Uc Preparaty kombinowane darunawiru
PL2742051T3 (pl) 2011-09-14 2017-06-30 Mapi Pharma Limited Amorficzna postać soli sodowej dolutegrawiru
EP2774928B1 (en) 2011-10-12 2017-08-30 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
CN104114559B (zh) 2011-12-12 2016-08-24 拜耳知识产权有限责任公司 氨基取代的咪唑并哒嗪
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
WO2014008636A1 (en) 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
US20150166520A1 (en) 2012-07-20 2015-06-18 Merck Sharp & Dohme Corp. Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
US20150218164A1 (en) 2012-07-25 2015-08-06 Merck Sharp & Dohme Corp. Substituted naphthyridinedione derivatives as hiv integrase inhibitors
US8877931B2 (en) 2012-08-03 2014-11-04 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
SG11201503397YA (en) 2012-11-08 2015-05-28 Bristol Myers Squibb Co Heteroaryl substituted pyridyl compounds useful as kinase modulators
MA38182A1 (fr) 2012-12-14 2018-04-30 Glaxosmithkline Llc Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
US9714243B2 (en) 2012-12-17 2017-07-25 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as HIV integrase inhibitors
DK3067358T3 (da) 2012-12-21 2019-11-04 Gilead Sciences Inc Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
US20140221355A1 (en) 2012-12-21 2014-08-07 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2934482A4 (en) 2012-12-21 2016-07-20 Merck Sharp & Dohme ADMINISTRATIVE FORMULATIONS
SG11201504982PA (en) 2012-12-27 2015-07-30 Japan Tobacco Inc SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
NO2865735T3 (OSRAM) 2013-07-12 2018-07-21
PL3019503T3 (pl) 2013-07-12 2018-01-31 Gilead Sciences Inc Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
EP3049081B1 (en) 2013-09-27 2019-11-27 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9856271B2 (en) 2014-01-21 2018-01-02 Laurus Labs Limited Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
WO2015138933A1 (en) 2014-03-13 2015-09-17 Assia Chemical Industries Ltd. Solid state forms of dolutegravir sodium
NO2717902T3 (OSRAM) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EA201790024A1 (ru) * 2014-07-11 2017-07-31 Джилид Сайэнс, Инк. Модуляторы toll-подобных рецепторов для лечения вич
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3277691B1 (en) 2015-04-02 2019-01-30 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
SI3316868T1 (sl) 2015-06-30 2020-04-30 Gilead Sciences, Inc. Farmacevtske formulacije, ki vsebujejo tenofovir in emtricitabin
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
BR102016026127A2 (pt) 2015-11-09 2017-05-16 Gilead Sciences Inc composições terapêuticas para o tratamento do vírus da imunodeficiência humana

Also Published As

Publication number Publication date
EP3067358A1 (en) 2016-09-14
PH12015501445B1 (en) 2015-09-14
AR094197A1 (es) 2015-07-15
NO2018026I1 (no) 2018-08-23
JP2023134483A (ja) 2023-09-27
IL247311A0 (en) 2016-09-29
AU2013361401B2 (en) 2017-01-05
CL2015001756A1 (es) 2015-08-07
JP2016508134A (ja) 2016-03-17
AU2013361401A1 (en) 2015-08-27
PH12015501445A1 (en) 2015-09-14
TW202104229A (zh) 2021-02-01
KR102120875B1 (ko) 2020-06-09
MD4754B1 (ro) 2021-05-31
MX2022013596A (es) 2022-11-16
IL245780A0 (en) 2016-08-02
US9216996B2 (en) 2015-12-22
MX372534B (es) 2020-03-23
HRP20191957T1 (hr) 2020-02-07
LUC00083I2 (en) 2018-10-15
LT3067358T (lt) 2019-11-25
AU2016262722B2 (en) 2018-10-18
PH12019501848A1 (en) 2020-03-02
BR122015029881A2 (pt) 2016-03-22
CN111303152B (zh) 2023-04-11
PL3067358T3 (pl) 2020-02-28
AU2018232957B2 (en) 2020-01-30
KR20190124814A (ko) 2019-11-05
PT2822954E (pt) 2016-06-16
LT3608325T (lt) 2022-09-12
IL239316A (en) 2016-09-29
HUE046559T2 (hu) 2020-03-30
MX357940B (es) 2018-07-31
US20140221356A1 (en) 2014-08-07
ES2926068T3 (es) 2022-10-21
US20170260204A1 (en) 2017-09-14
AU2018232957A1 (en) 2018-10-11
MD4736C1 (ro) 2021-07-31
TWI815245B (zh) 2023-09-11
AU2021221427B2 (en) 2023-10-12
UY35213A (es) 2014-06-30
CN116640140A (zh) 2023-08-25
CN104995198B (zh) 2018-01-30
JP6028105B2 (ja) 2016-11-16
KR102246963B1 (ko) 2021-04-30
JP6571256B2 (ja) 2019-09-04
AU2021221427A1 (en) 2021-09-16
MD20150064A2 (ro) 2015-11-30
HK1216643A1 (zh) 2016-11-25
SI2822954T1 (sl) 2016-07-29
NZ718708A (en) 2018-11-30
AU2020202914A1 (en) 2020-05-21
HUS1800035I1 (hu) 2018-09-28
US11548901B2 (en) 2023-01-10
JP7301918B2 (ja) 2023-07-03
KR101770048B1 (ko) 2017-08-21
CN107674086A (zh) 2018-02-09
PE20170528A1 (es) 2017-05-28
CY1117570T1 (el) 2017-04-26
EA037633B1 (ru) 2021-04-23
CY2018022I2 (el) 2019-07-10
ZA201903516B (en) 2020-01-29
CL2017001191A1 (es) 2018-02-09
HRP20160544T1 (hr) 2016-07-15
US10035809B2 (en) 2018-07-31
SMT201600157B (it) 2016-08-31
EP2822954B1 (en) 2016-03-09
BR122015029881B1 (pt) 2022-04-26
US9732092B2 (en) 2017-08-15
JP6411409B2 (ja) 2018-10-24
BR112015014714B1 (pt) 2018-12-26
HRP20220899T1 (hr) 2022-10-28
EP3608325B1 (en) 2022-07-06
RS54873B1 (sr) 2016-10-31
SG11201504857SA (en) 2015-07-30
US20160176885A1 (en) 2016-06-23
US20190092787A1 (en) 2019-03-28
ES2577283T3 (es) 2016-07-14
MD4841B1 (ro) 2023-01-31
IL239316A0 (en) 2015-07-30
HK1250711A1 (zh) 2019-01-11
HK1205124A1 (en) 2015-12-11
TWI830624B (zh) 2024-01-21
CA3131094A1 (en) 2014-06-26
MD4736B1 (ro) 2020-12-31
KR20200067930A (ko) 2020-06-12
US20170057976A1 (en) 2017-03-02
SI3608325T1 (sl) 2022-09-30
PE20151499A1 (es) 2015-10-29
MX2020003055A (es) 2020-07-27
JP2019023204A (ja) 2019-02-14
CR20170279A (es) 2017-10-19
LTC2822954I2 (lt) 2019-10-10
CA2893843C (en) 2018-09-04
JP2021193090A (ja) 2021-12-23
KR20230061576A (ko) 2023-05-08
ZA201507997B (en) 2019-09-25
CA2893843A1 (en) 2014-06-26
EP3608325A1 (en) 2020-02-12
CA3012242C (en) 2021-11-02
DK3608325T3 (da) 2022-08-22
EP4122935A1 (en) 2023-01-25
CY2018022I1 (el) 2019-07-10
EA201890236A1 (ru) 2018-10-31
CN104995198A (zh) 2015-10-21
WO2014100323A1 (en) 2014-06-26
KR102527797B1 (ko) 2023-05-03
UA123572C2 (uk) 2021-04-28
DK2822954T3 (en) 2016-05-30
KR20210049956A (ko) 2021-05-06
KR102406288B1 (ko) 2022-06-13
AU2023286038A1 (en) 2024-01-25
TWI752457B (zh) 2022-01-11
PH12016500389B1 (en) 2018-10-01
AU2013361401C1 (en) 2018-08-09
AU2020202914B2 (en) 2021-09-09
KR20220080208A (ko) 2022-06-14
MY191741A (en) 2022-07-13
IL245780B (en) 2019-02-28
JP2016179996A (ja) 2016-10-13
EP2822954A1 (en) 2015-01-14
CA3012242A1 (en) 2014-06-26
TWI642669B (zh) 2018-12-01
HUE059688T2 (hu) 2022-12-28
US20210053988A1 (en) 2021-02-25
HUE028284T2 (en) 2016-12-28
ES2753548T3 (es) 2020-04-13
IL274988A (en) 2020-07-30
CR20150380A (es) 2015-08-21
EA030003B1 (ru) 2018-06-29
EA201591027A1 (ru) 2016-05-31
TWI693224B (zh) 2020-05-11
MY164352A (en) 2017-12-15
CY1122246T1 (el) 2020-11-25
EP3067358B1 (en) 2019-08-07
DK3067358T3 (da) 2019-11-04
PL2822954T3 (pl) 2016-09-30
AU2016262722A1 (en) 2016-12-08
PH12016500389A1 (en) 2018-10-01
MX344879B (es) 2017-01-11
LTPA2018511I1 (lt) 2018-10-10
CL2016000837A1 (es) 2016-10-21
MD20200093A2 (ro) 2021-05-31
BR112015014714A2 (pt) 2016-01-05
ME02400B (me) 2016-09-20
KR20220011789A (ko) 2022-01-28
KR20150096504A (ko) 2015-08-24
MD4754C1 (ro) 2021-12-31
JP6933690B2 (ja) 2021-09-08
SI3067358T1 (sl) 2019-12-31
PT3608325T (pt) 2022-10-17
KR20170073733A (ko) 2017-06-28
US9663528B2 (en) 2017-05-30
MX2015008009A (es) 2015-10-22
KR102351912B1 (ko) 2022-01-17
NZ709260A (en) 2016-07-29
US10689399B2 (en) 2020-06-23
CN111303152A (zh) 2020-06-19
KR102040007B1 (ko) 2019-11-05
TW202400591A (zh) 2024-01-01
TW201918485A (zh) 2019-05-16
TW202212342A (zh) 2022-04-01
CN107674086B (zh) 2020-03-31
JP2019218368A (ja) 2019-12-26
AP2015008510A0 (en) 2015-06-30
NO2018026I2 (no) 2018-08-23
NL300947I2 (nl) 2018-09-26
JP2025138660A (ja) 2025-09-25
UA114351C2 (uk) 2017-05-25
TW201441224A (zh) 2014-11-01
PL3608325T3 (pl) 2022-11-07

Similar Documents

Publication Publication Date Title
IL274988A (en) Carbamoylpyridone-polycyclic compounds and their pharmaceutical use
IL234628A0 (en) Imidazolyl-pyrimidines are converted into amino-indolyl and their use as drugs
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
EP2718283A4 (en) INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
ZA201501930B (en) Pharmaceutical composition
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
IL251974B (en) Antifibrosis compounds and their uses
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
ZA201409020B (en) Pharmaceutical formulation
ZA201405392B (en) Substituted phenylimidazopyrazoles and use thereof
IL235830A0 (en) New dosage and formulation
HUE037618T2 (hu) Gyógyszerészeti kombinációk
ZA201502987B (en) Pharmaceutical composition
EP2940008A4 (en) Novel benzazepine derivative and pharmaceutical use thereof
GB201213726D0 (en) Novel compounds and their use
GB201216381D0 (en) New compounds and medical uses
GB201208970D0 (en) New compounds and medical uses
GB201214749D0 (en) Compounds and their uses
ZA201400751B (en) Pharmaceutical composition